As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.
12 Analysts have issued a Abeona Therapeutics, Inc. forecast:
12 Analysts have issued a Abeona Therapeutics, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 0.40 0.40 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -71 -71 |
32%
32%
|
EBIT (Operating Income) EBIT | -75 -75 |
31%
31%
|
Net Profit | 57 57 |
209%
209%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Head office | United States |
CEO | Vishwas Seshadri |
Employees | 136 |
Founded | 1974 |
Website | abeonatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.